Modification of outcomes with aspirin or apixaban in relation to CHADS 2 and CHA2DS2-VASc scores in patients with atrial fibrillation: A secondary analysis of the AVERROES study

Circulation: Arrhythmia and Electrophysiology

Volumn 6, Issue 1, 2013, Pages 31-38

  Lip, Gregory Y H ^a   Connolly, Stuart ^b   Yusuf, Salim ^b   Shestakovska, Olga ^b   Flaker, Greg ^c   Hart, Robert ^b   Lanas, Fernando ^d   Xavier, Denis ^e   Eikelboom, John ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF MISSOURI   (United States)

^d UNIVERSIDAD DE LA FRONTERA   (Chile)

^e ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

Author keywords

Apixaban; Aspirin; Atrial fibrillation; Risk stratification; Stroke prevention

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; FIBRINOLYTIC AGENT; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

AGED; ARTICLE; BLEEDING; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; FEMALE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SECONDARY ANALYSIS; TRANSIENT ISCHEMIC ATTACK; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEALTH STATUS INDICATOR; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

AGED; ASPIRIN; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; FEMALE; FIBRINOLYTIC AGENTS; HEALTH STATUS INDICATORS; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PYRAZOLES; PYRIDONES; RISK ASSESSMENT; RISK FACTORS; STROKE; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84876298893     PISSN: 19413149     EISSN: 19413084     Source Type: Journal    
DOI: 10.1161/CIRCEP.112.975847     Document Type: Article

References (29)

1. Lip GY. Anticoagulation therapy and the risk of stroke in patients with atrial fibrillation at 'moderate risk' [CHADS2 score=1]: simplifying stroke risk assessment and thromboprophylaxis in real-life clinical practice. Thromb Haemost. 2010;103:683-685.
2. Potpara TS, Stankovic GR, Beleslin BD, Polovina MM, Marinkovic JM, Ostojic MC, Lip GY. A 12-year follow-up study of patients with newly diagnosed lone atrial fibrillation: implications of arrhythmia progression on prognosis: the Belgrade Atrial Fibrillation study. Chest. 2012;141:339-347.
3. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864-2870.
4. Karthikeyan G, Eikelboom JW. The CHADS2 score for stroke risk stratification in atrial fibrillation-friend or foe? Thromb Haemost. 2010;104:45-48.
5. 2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost. 2012;107:1172-1179.
6. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263-272.
7. Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, Selmer C, Ahlehoff O, Olsen AM, Gislason GH, Torp-Pedersen C. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124.
8. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O'Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806-817.
9. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-612.
10. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, Murray E; BAFTA investigators; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370:493-503.
11. Rash A, Downes T, Portner R, Yeo WW, Morgan N, Channer KS. A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing. 2007;36:151-156.
12. Lip GY. The role of aspirin for stroke prevention in atrial fibrillation. Nat Rev Cardiol. 2011;8:602-606.
13. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369-2429.
14. Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, Lane D, Levi M, Marín F, Palareti G, Kirchhof P; European Heart Rhythm Association. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost. 2011;106:997-1011.
15. Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P, Bankhead C, Xu Y. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes. 2008;1:84-91.
16. Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost. 2010;104:49-60.
17. Ahrens I, Lip GY, Peter K. What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation? Thromb Haemost. 2011;105:574-578.
18. Eckman MH, Singer DE, Rosand J, Greenberg SM. Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2011;4:14-21.
19. Olesen JB, Lip GY, Lindhardsen J, Lane DA, Ahlehoff O, Hansen ML, Raunsø J, Tolstrup JS, Hansen PR, Gislason GH, Torp-Pedersen C. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost. 2011;106:739-749.
20. Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology. 2007;69:546-554.
21. Pisters R, Lane DA, Marin F, Camm AJ, Lip GY. Stroke and thromboembolism in atrial fibrillation. Circ J. 2012;76:2289-2304.
22. Lip GY, Frison L, Grind M; SPORTIF Invetigators. Effect of hypertension on anticoagulated patients with atrial fibrillation. Eur Heart J. 2007;28:752-759.
23. Ho LY, Siu CW, Yue WS, Lau CP, Lip GY, Tse HF. Safety and efficacy of oral anticoagulation therapy in Chinese patients with concomitant atrial fibrillation and hypertension. J Hum Hypertens. 2011;25:304-310.
24. Kalra L, Lip GY; Guideline Development Group for the NICE clinical guideline for the management of atrial fibrillation. Antithrombotic treatment in atrial fibrillation. Heart. 2007;93:39-44.
25. Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials. Arch Intern Med. 1998;158:1316-1320.
26. Lin LY, Lee CH, Yu CC, Tsai CT, Lai LP, Hwang JJ, Chen PC, Lin JL. Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation - a nation wide database analysis. Atherosclerosis. 2011;217:292-295.
27. Marinigh R, Lane DA, Lip GY. Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol. 2011;57:1339-1348.
28. Nieuwlaat R, Dinh T, Olsson SB, Camm AJ, Capucci A, Tieleman RG, Lip GY, Crijns HJ; Euro Heart Survey Investigators. Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation? Eur Heart J. 2008;29:915-922.
29. 2-VASc risk scores in patients with paroxysmal atrial fibrillation by continuous arrhythmia burden monitoring. Stroke. 2011;42:1768-1770.